Supplementary Fig. S3. Succinate induces phenotypic switching of SMCs. (**a**) Real-time PCR analysis of the mRNA expression of SMCs marker (*α-SMA, SM22α, Calponin*) and endothelial marker (*CD144, vWF, CD31, eNOS*) in the indicated times after succinate treatments. *GAPDH* serves as the internal control. (**b**) IB analysis of expression of p-ERK1/2, ERK1/2, p-Elk1, Elk1 and nuclear-KLF4 in PBSMCs treated by SFC-MI-PDBCs#1/#3, with or without SUCNR1 inhibitor 4C and MAPK/ERK inhibitor PD98059. GAPDH served as the loading control. H3 serve as a loading control for nuclear protein. (**c**) IB analysis of expression of SLC13A3, SLC13A2, SLC13A5, SLC25A10, MCT1, MCT2 and MCT4 in the indicated PBSMCs. GAPDH served as the loading control. (**d**) $^{13}C_4$-succinate uptake was measured in the PBSMCs that treated with control, succinate or SFC/MI-PDBCs#1 transduced with or without MCT1 siRNA. (**e**) Real-time PCR analysis of the mRNA expression of *iNOS* in the indicated times after succinate or SFC-MI-PDBCs#1treatments. *GAPDH* serves as the internal control. (**f**) Co-IP/IB analysis of succinylated iNOS in the indicated cells. (**g**) Co-IP/IB analysis of succinylated iNOS in the cells transduced with FLAG-wild-type-iNOS, iNOS-K22R, iNOS-K505R, iNOS-K516R and iNOS-K613R. (**h**) IB analysis of the protein degradation rate of iNOS in the cells that transduced with FLAG-wild-type-iNOS or iNOS-K22R. (**i**) Co-IP/IB analysis of the level of polyubiquitinated iNOS-WT and iNOS-K22R. Each error bar in a, d and e represents the mean ± SD of three independent experiments. Statistical analysis was performed using Two-way ANOVA with Šídák's multiple comparisons test for (d), and one-way ANOVA with Dunnett's multiple comparison tests for (e). ***$P < 0.001$; ns, not significant.

Supplementary Fig. S3